A Pilot Randomized Clinical Trial of Pediatric Cystic Fibrosis Pulmonary Exacerbations Treatment Strategies
Rationale: Despite the high prevalence and clear morbidity of cystic fibrosis (CF) pulmonary exacerbations (PEx), there have been no published clinical trials of outpatient exacerbation management. Objectives: To assess the feasibility of a pediatric clinical trial in which treatment of mild PEx is assigned randomly to immediate oral antibiotics or tailored therapy (increased airway clearance alone with oral antibiotics added only for prespecified criteria). The outcome on which sample size was based was the proportion of tailored therapy participants who avoided oral antibiotics during the 28 days after randomization. Methods: In this randomized, open-label, pilot feasibility study at 10 U.S. sites, children 6-18 years of age with CF were enrolled at their well baseline visits and followed through their first randomized PEx. Results: One hundred twenty-one participants were enrolled, of whom 94 (78%) reported symptoms of PEx at least once; of these, 81 (86%) had at least one exacerbation that met randomization criteria, of whom 63 (78%) were randomized. Feasibility goals were met, including enrollment, early detection of symptoms of PEx, and ability to randomize. Among the 33 participants assigned to tailored therapy, 10 (30%) received oral antibiotics, while 29 of 30 (97%) assigned to immediate antibiotics received oral antibiotics. The avoidance of oral antibiotics in 70% (95% confidence interval, 54-85%) was statistically significantly different from our null hypothesis that <10% of participants assigned to the tailored therapy arm would avoid antibiotics. Conclusions: Our pilot study demonstrates that conducting a randomized trial of oral antibiotic treatment strategies for mild PEx in children with CF is feasible and that assignment to a tailored therapy arm may reduce antibiotic exposure. Clinical trial registered with www.clinicaltrials.gov (NCT04608019).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Annals of the American Thoracic Society - 20(2023), 12 vom: 11. Dez., Seite 1769-1776 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sanders, Don B [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Bacterial Agents |
|---|
| Anmerkungen: |
Date Completed 04.12.2023 Date Revised 18.12.2023 published: Print ClinicalTrials.gov: NCT04608019 Citation Status MEDLINE |
|---|
| doi: |
10.1513/AnnalsATS.202303-245OC |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361806477 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361806477 | ||
| 003 | DE-627 | ||
| 005 | 20231227133652.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1513/AnnalsATS.202303-245OC |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1231.xml |
| 035 | |a (DE-627)NLM361806477 | ||
| 035 | |a (NLM)37683122 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sanders, Don B |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Pilot Randomized Clinical Trial of Pediatric Cystic Fibrosis Pulmonary Exacerbations Treatment Strategies |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.12.2023 | ||
| 500 | |a Date Revised 18.12.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT04608019 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Rationale: Despite the high prevalence and clear morbidity of cystic fibrosis (CF) pulmonary exacerbations (PEx), there have been no published clinical trials of outpatient exacerbation management. Objectives: To assess the feasibility of a pediatric clinical trial in which treatment of mild PEx is assigned randomly to immediate oral antibiotics or tailored therapy (increased airway clearance alone with oral antibiotics added only for prespecified criteria). The outcome on which sample size was based was the proportion of tailored therapy participants who avoided oral antibiotics during the 28 days after randomization. Methods: In this randomized, open-label, pilot feasibility study at 10 U.S. sites, children 6-18 years of age with CF were enrolled at their well baseline visits and followed through their first randomized PEx. Results: One hundred twenty-one participants were enrolled, of whom 94 (78%) reported symptoms of PEx at least once; of these, 81 (86%) had at least one exacerbation that met randomization criteria, of whom 63 (78%) were randomized. Feasibility goals were met, including enrollment, early detection of symptoms of PEx, and ability to randomize. Among the 33 participants assigned to tailored therapy, 10 (30%) received oral antibiotics, while 29 of 30 (97%) assigned to immediate antibiotics received oral antibiotics. The avoidance of oral antibiotics in 70% (95% confidence interval, 54-85%) was statistically significantly different from our null hypothesis that <10% of participants assigned to the tailored therapy arm would avoid antibiotics. Conclusions: Our pilot study demonstrates that conducting a randomized trial of oral antibiotic treatment strategies for mild PEx in children with CF is feasible and that assignment to a tailored therapy arm may reduce antibiotic exposure. Clinical trial registered with www.clinicaltrials.gov (NCT04608019) | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a clinical trial | |
| 650 | 4 | |a oral antibiotic therapy | |
| 650 | 4 | |a respiratory infection | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 700 | 1 | |a Bartz, Traci M |e verfasserin |4 aut | |
| 700 | 1 | |a Zemanick, Edith T |e verfasserin |4 aut | |
| 700 | 1 | |a Hoppe, Jordana E |e verfasserin |4 aut | |
| 700 | 1 | |a Hinckley Stukovsky, Karen D |e verfasserin |4 aut | |
| 700 | 1 | |a Cogen, Jonathan D |e verfasserin |4 aut | |
| 700 | 1 | |a Bendy, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a McNamara, Sharon |e verfasserin |4 aut | |
| 700 | 1 | |a Enright, Erika |e verfasserin |4 aut | |
| 700 | 1 | |a Kime, Noah A |e verfasserin |4 aut | |
| 700 | 1 | |a Kronmal, Richard A |e verfasserin |4 aut | |
| 700 | 1 | |a Edwards, Todd C |e verfasserin |4 aut | |
| 700 | 1 | |a Morgan, Wayne J |e verfasserin |4 aut | |
| 700 | 1 | |a Rosenfeld, Margaret |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of the American Thoracic Society |d 2013 |g 20(2023), 12 vom: 11. Dez., Seite 1769-1776 |w (DE-627)NLM225943336 |x 2325-6621 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2023 |g number:12 |g day:11 |g month:12 |g pages:1769-1776 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1513/AnnalsATS.202303-245OC |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2023 |e 12 |b 11 |c 12 |h 1769-1776 | ||